Dosing and uses of Tetanus toxoid adsorbed or fluid
Primary Immunization
0.5 mL IM; repeat at 4-8weeks after first dose and at 6-12 months after second dose
Booster: 0.5 mL IM q10Years
Additional Information
Up-to-date vaccination schedules available at www.cdc.gov/nip/publications
Other Indications & Uses
Selective immunization against tetanus (use trivalent DTP for routine Peds immunization)
Pediatric dosage forms and strengths
Primary Immunization
< 7 Years
- Safety and efficacy not established
> 7 Years
- 0.5 mL IM; repeat at 4-8weeks after first dose and at 6-12 months after second dose
- Booster: 0.5 mL IM q10Years
- Use trivalent DTP for routine Peds immunization
Geriatric dosage forms and strengths
Primary Immunization
0.5 mL IM; repeat at 4-8weeks after first dose and at 6-12 months after second dose
Booster: 0.5 mL IM q10Years
Tetanus toxoid adsorbed or fluid adverse (side) effects
Suspected adverse events after administration of any vaccine may be reported to Vaccine Adverse Events Reporting System (VAERS), 1-800-822-7967
Frequency not defined
Malaise
Rash
Arthus reaction
Nausea
Hypotension
Fever
Guillain-Barre syndrome
EEG disturbances
Warnings
Contraindications
Hypersensitivity to ThimerosaL
Delay if acute/febrile illness
Cautions
Adults: DT toxoids preferred
For passive immunization, use Tetanus Immune Globulin (TIG)
Adsorbed to aluminum for greater immunogenicity
Need 3 doses for primary immunization
Alternative is fluid toxoid for use if hypersensitive to aluminum
Need four 0.5 mL doses for primary immunization
Children <7 years
- Not recommended, use instead:
- Diphtheria, Tetanus toxoids, and Acellular Pertussis vaccine (DTaP), or
- Diphtheria, Tetanus toxoids, and Pertussis vaccine (DTP), or
- Diphtheria and Tetanus Toxoids (DT)
Pregnancy and lactation
Pregnancy category: C
Lactation: not known if excreted in breast milk
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of Tetanus toxoid adsorbed or fluid
Mechanism of action
Active immunization by toxoid-induced Ab production against Clostridium tetani exotoxin
Pharmacokinetics
These products convey active immunity via stimulation of production of endogenously produced antibodies
The onset of protection from disease is relatively slow, but duration is long lasting (years)
Duration: 10 year
Bioavailability: 100%
